IL-13 and TLR2 heterodimer agonists can upregulate the transcription of IL-13Rα2 in keratinocytes and sensory neurons, respectively [149], thereby promoting neurogenic inflammation and exacerbating AD and itch. This evidence concerns the gene IL13RA2 and Alzheimer disease.